21 CFR 640.64
Collection of blood for Source Plasma.
- Inspections citing it: 26
- Of those classified, ended OAI: 0%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Regulation Text
eCFR, as of Nov 6, 2026(a) [Reserved]
(b) Blood containers. Blood containers and donor sets must be pyrogen-free, sterile, and identified by lot number.
(c) The anticoagulant solution. The anticoagulant solution must be sterile and pyrogen-free. Anticoagulant solutions must be compounded and used according to a formula that has been approved for the applicant by the Director, Center for Biologics Evaluation and Research.
(d) Donor identification. Each unit of blood and plasma shall be so marked or identified by number or other symbol so as to relate it directly to the donor.
(e) Prevention of contamination of the blood and plasma. The skin of the donor at the site of phlebotomy shall be prepared thoroughly and carefully by a method that gives maximum assurance of a sterile container of blood. The blood shall be collected, the plasma separated, and the cells returned to the donor by aseptic methods in a sterile system which may be closed, or may be vented if the vent protects the blood cells and plasma against contamination.
Recently Cited Sites
Newest inspections citing this section; each opens the site- CSL Plasma IncUnited States · Feb 6, 2026
- Central California Blood CenterUnited States · Aug 29, 2025
- Biomat Holdings Mount Vernon NewarkUnited States · Jul 15, 2025
- DB Biologics, LLCUnited States · Jun 18, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR